Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Study of ExAblate Focused Ultrasound Ablation of Breast Cancer

NCT: NCT01620359 · COMPLETED

NCT IDNCT01620359
StatusCOMPLETED
Start Date2010-11-24
Completion2014-04-14
SponsorInSightec (INDUSTRY)
First posted
Last updated

Brief Summary

The goal of this prospective, non-randomized, single-arm, multi site, international study is to develop data to evaluate the safety and effectiveness of the ExAblate MRgFUS system in the ablation of breast cancer and of MRI. The goal of MRgFUS ablation of breast cancer is to plan and ablate the entire tumor volume in a treatable and device accessible location.

Frequently Asked Questions

What is Study of ExAblate Focused Ultrasound Ablation of Breast Cancer?

Study of ExAblate Focused Ultrasound Ablation of Breast Cancer is a clinical trial registered under NCT01620359. Current status: COMPLETED.

What is the status of NCT01620359?

The current status of NCT01620359 (Study of ExAblate Focused Ultrasound Ablation of Breast Cancer) is: COMPLETED.

When did Study of ExAblate Focused Ultrasound Ablation of Breast Cancer start?

Study of ExAblate Focused Ultrasound Ablation of Breast Cancer started on 2010-11-24.

Related Devices

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.